The interaction between NK cells and ILC cells and their subsets in atopic dermatitis patients with and without dupilumab therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F24%3A10480887" target="_blank" >RIV/00179906:_____/24:10480887 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11150/24:10480887

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=nY4K6hwz8f" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=nY4K6hwz8f</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.intimp.2024.112327" target="_blank" >10.1016/j.intimp.2024.112327</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The interaction between NK cells and ILC cells and their subsets in atopic dermatitis patients with and without dupilumab therapy

Popis výsledku v původním jazyce

Background: Natural killer cells (NK) and innate lymphoid cells with their subsets (ILC) are part of the innate immune system. Objective: The aim is to evaluate how NK cells and ILC cells interact in atopic dermatitis (AD) patients (with and without dupilumab therapy) compared to control group. Materials and Methods: Complete dermatological examination was performed in all patients included in the study (19 AD patients with dupilumab, 17 AD patients without dupilumab). Surface molecules expressed on NK cells and ILC cells were analyzed by flow cytometry. The association between NK cells and total ILC cells, ILC-1, ILC-2, ILC-3, NCR+ILC3, NCR - ILC3 were compared in AD patients and in the control group. The non -parametric Spearman &apos;s rank correlation coefficient was used for this statistical analysis. We evaluated the association of parameters with AD severity at the time of treatment.Non-parametric Mann -Whitney, Kolmogorov-Smirnov tests were used. Results: We confirmed the higher association between NK cells and total ILC cells in AD patients without dupilumab therapy (in 30.3 %) and in healthy controls (in 27.2 %); this association is low in AD patients with dupilumab therapy (in 0.1 %). The higher association was confirmed between NK cells and ILCs subsets only in AD patients without dupilumab therapy; in these patients the highest association was confirmed between NK cells and ILC-2 cells (in 38.6 %). No statistically significant difference in the count of NK cells and ILC cells was found between mild and moderate form of AD patients treated with dupilumab. Conclusion: Targeting these cell types or the cytokines they produce could represent potential therapeutic strategies for controlling inflammation and alleviating symptoms in AD patients.

Název v anglickém jazyce

The interaction between NK cells and ILC cells and their subsets in atopic dermatitis patients with and without dupilumab therapy

Popis výsledku anglicky

Background: Natural killer cells (NK) and innate lymphoid cells with their subsets (ILC) are part of the innate immune system. Objective: The aim is to evaluate how NK cells and ILC cells interact in atopic dermatitis (AD) patients (with and without dupilumab therapy) compared to control group. Materials and Methods: Complete dermatological examination was performed in all patients included in the study (19 AD patients with dupilumab, 17 AD patients without dupilumab). Surface molecules expressed on NK cells and ILC cells were analyzed by flow cytometry. The association between NK cells and total ILC cells, ILC-1, ILC-2, ILC-3, NCR+ILC3, NCR - ILC3 were compared in AD patients and in the control group. The non -parametric Spearman &apos;s rank correlation coefficient was used for this statistical analysis. We evaluated the association of parameters with AD severity at the time of treatment.Non-parametric Mann -Whitney, Kolmogorov-Smirnov tests were used. Results: We confirmed the higher association between NK cells and total ILC cells in AD patients without dupilumab therapy (in 30.3 %) and in healthy controls (in 27.2 %); this association is low in AD patients with dupilumab therapy (in 0.1 %). The higher association was confirmed between NK cells and ILCs subsets only in AD patients without dupilumab therapy; in these patients the highest association was confirmed between NK cells and ILC-2 cells (in 38.6 %). No statistically significant difference in the count of NK cells and ILC cells was found between mild and moderate form of AD patients treated with dupilumab. Conclusion: Targeting these cell types or the cytokines they produce could represent potential therapeutic strategies for controlling inflammation and alleviating symptoms in AD patients.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Immunopharmacology

ISSN

1567-5769

e-ISSN

1878-1705

Svazek periodika

136

Číslo periodika v rámci svazku

JUL

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

112327

Kód UT WoS článku

001249291600005

EID výsledku v databázi Scopus

2-s2.0-85194372367